Exploration of Digestive Diseases

Articles

Latest

Most Viewed

Most Downloaded

Most Cited

Open Access Original Article

Fructose induces metabolic reprogramming in liver cancer cells, promoting aggressiveness and chemotherapy resistance

Aim: Fructose is a highly lipogenic compound related to the onset of steatosis, its progression to steatohepatitis, and the eventual initiation of hepatocellular carcinoma (HCC). One of the cance

Published: April 20, 2025 Explor Dig Dis. 2025;4:100572

DOI: https://doi.org/10.37349/edd.2025.100572

Full Text PDF

168 14 0

Open Access Perspective

Molecular insights into pancreatic cysts: navigating diagnosis and precision management

Pancreatic cystic lesions are frequently found incidentally on cross-sectional imaging and are broadly classified into mucinous and non-mucinous cysts. While some exhibit benign behavior, others hav

Published: April 13, 2025 Explor Dig Dis. 2025;4:100571

DOI: https://doi.org/10.37349/edd.2025.100571

Full Text PDF

174 4 0

Open Access Perspective

Debugging surgical guidelines for acute diverticulitis

Diverticular disease of the colon is a very important digestive disease and its management depends on the characteristics of the disease and the patient and the resources available. There are benefi

Published: April 11, 2025 Explor Dig Dis. 2025;4:100570

DOI: https://doi.org/10.37349/edd.2025.100570

Full Text PDF

108 5 0

Open Access Review

The multiple mechanisms and modes of cell death after acetaminophen overdose

Acetaminophen (APAP)-induced liver injury and acute liver failure is a significant clinical problem worldwide; in addition, APAP overdoses in animals or in cell culture are used as popular models to

Published: April 07, 2025 Explor Dig Dis. 2025;4:100569

DOI: https://doi.org/10.37349/edd.2025.100569

Full Text PDF

238 9 1

Open Access Original Article

Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study

Aim: Selecting patients for immunotherapy in metastatic gastric cancer (mGC) in second and subsequent lines remains challenging. The aim of our study is to assess the feasibility of anti-programm

Published: March 27, 2025 Explor Dig Dis. 2025;4:100568

DOI: https://doi.org/10.37349/edd.2025.100568

Full Text PDF

327 13 0

Open Access Letter to the Editor

Helicobacter pylori infection in the pathophysiology of metabolic dysfunction-associated steatotic liver disease and its complications

Published: March 20, 2025 Explor Dig Dis. 2025;4:100567

DOI: https://doi.org/10.37349/edd.2025.100567

Full Text PDF

185 5 0

Open Access Review

Drug-induced cholestasis: causative agents and challenges in diagnosis and management

Drug-induced liver injury (DILI) is an adverse reaction to drugs and other xenobiotics that can have serious consequences and jeopardise progress in pharmacological therapy. While DILI is predominan

Published: September 18, 2023 Explor Dig Dis. 2023;2:202–222

DOI: https://doi.org/10.37349/edd.2023.00027

Full Text PDF

14464 220 3

Open Access Review

Etiopathogenesis and pathophysiology of cholestasis

Normal hepatobiliary function depends on an adequate bile flow from the liver through the biliary tree to the gallbladder, where bile is stored and concentrated, and from the gallbladder to the duod

Published: October 31, 2022 Explor Dig Dis. 2022;1:97–117

DOI: https://doi.org/10.37349/edd.2022.00008

Full Text PDF

9917 297 2

Open Access Review

Fructose, a trigger of metabolic diseases?—a narrative review

Worldwide the number of individuals being overweight or obese has dramatically increased during the last decades, which is also associated with a similar dramatic increase of individuals afflicted w

Published: August 29, 2022 Explor Dig Dis. 2022;1:51–71

DOI: https://doi.org/10.37349/edd.2022.00005

Full Text PDF

7407 161 2

Open Access Review

Excessive alcohol intake is still among the leading causes of chronic liver diseases. Epidemiological studies suggest that per capita consumption of alcohol from various alcohol beverages e.g., beer

Published: June 30, 2023 Explor Dig Dis. 2023;2:118–132

DOI: https://doi.org/10.37349/edd.2023.00022

Full Text PDF

7139 80 3

Open Access Review

Helicobacter pylori and gastric cancer: a critical approach to who really needs eradication

It is generally accepted that eradication of Helicobacter pylori (H. pylori) infection may reduce the risk of the development of gastric cancer. Recommendations for global generalized tests and trea

Published: April 16, 2024 Explor Dig Dis. 2024;3:107–142

DOI: https://doi.org/10.37349/edd.2024.00043

Full Text PDF

6002 107 5

Open Access Review

Hepatitis B virus: modes of transmission, immune pathogenesis, and research progress on therapeutic vaccines

Hepatitis B virus (HBV) infection affects 262 million people worldwide, leading to over 820,000 deaths annually. The reason HBV has been a persistent issue for decades is that it is a non-cytopathic

Published: October 14, 2024 Explor Dig Dis. 2024;3:443–458

DOI: https://doi.org/10.37349/edd.2024.00060

Full Text PDF

5725 104 0

Open Access Review

Etiopathogenesis and pathophysiology of cholestasis

Normal hepatobiliary function depends on an adequate bile flow from the liver through the biliary tree to the gallbladder, where bile is stored and concentrated, and from the gallbladder to the duod

Published: October 31, 2022 Explor Dig Dis. 2022;1:97–117

DOI: https://doi.org/10.37349/edd.2022.00008

Full Text PDF

9917 297 2

Open Access Review

Drug-induced cholestasis: causative agents and challenges in diagnosis and management

Drug-induced liver injury (DILI) is an adverse reaction to drugs and other xenobiotics that can have serious consequences and jeopardise progress in pharmacological therapy. While DILI is predominan

Published: September 18, 2023 Explor Dig Dis. 2023;2:202–222

DOI: https://doi.org/10.37349/edd.2023.00027

Full Text PDF

14464 220 3

Open Access Review

Fructose, a trigger of metabolic diseases?—a narrative review

Worldwide the number of individuals being overweight or obese has dramatically increased during the last decades, which is also associated with a similar dramatic increase of individuals afflicted w

Published: August 29, 2022 Explor Dig Dis. 2022;1:51–71

DOI: https://doi.org/10.37349/edd.2022.00005

Full Text PDF

7407 161 2

Open Access Review

Zebrafish as a model for drug induced liver injury: state of the art and beyond

Zebrafish as a preclinical drug induced liver injury (DILI) model provides multiple advantages ranging from ease of breeding and maintenance, availability of different strains and transgenic fish am

Published: April 26, 2023 Explor Dig Dis. 2023;2:44–55

DOI: https://doi.org/10.37349/edd.2023.00017

Full Text PDF

4647 134 3

Open Access Review

Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide, with a progressive form of non-alcoholic steatohepatitis (NASH). It may progress to advanced liver diseases,

Published: October 25, 2023 Explor Dig Dis. 2023;2:246–275

DOI: https://doi.org/10.37349/edd.2023.00029

Full Text PDF

3727 107 1

Open Access Review

Helicobacter pylori and gastric cancer: a critical approach to who really needs eradication

Published: April 16, 2024 Explor Dig Dis. 2024;3:107–142

DOI: https://doi.org/10.37349/edd.2024.00043

Full Text PDF

6002 107 5

Open Access Editorial

Extra-hepatic cancers in metabolic fatty liver syndromes

Published: February 24, 2023 Explor Dig Dis. 2023;2:11–17

DOI: https://doi.org/10.37349/edd.2023.00014

Full Text PDF

2139 39 6

Open Access Review

Helicobacter pylori and gastric cancer: a critical approach to who really needs eradication

Published: April 16, 2024 Explor Dig Dis. 2024;3:107–142

DOI: https://doi.org/10.37349/edd.2024.00043

Full Text PDF

6002 107 5

Open Access Review

Extracellular vesicles in metabolic dysfunction associated fatty liver disease: mechanisms, diagnostic and therapeutic implications

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) is increasing rapidly worldwide due to the obesity epidemic. Advanced stages of the MAFLD, such as non-alcoholic steato

Published: July 13, 2022 Explor Dig Dis. 2022;1:4–20

DOI: https://doi.org/10.37349/edd.2022.00002

Full Text PDF

4364 92 4

Open Access Review

Principles of risk stratification in nonalcoholic fatty liver disease. A narrative review emphasizing non-invasive strategies

Nonalcoholic fatty liver disease (NAFLD) is an umbrella definition that describes the ectopic deposition of fat within the liver that occurs in the absence of inciting factors other than the metabol

Published: August 30, 2023 Explor Dig Dis. 2023;2:188–201

DOI: https://doi.org/10.37349/edd.2023.00026

Full Text PDF

2682 54 4

Open Access Perspective

The intermicrovillar adhesion complex in gut barrier function and inflammation

The surface of intestinal epithelial cells is covered by the brush border, which consists of densely packed cellular extrusions called microvilli. Until recently, microvilli have not been known to b

Published: October 11, 2022 Explor Dig Dis. 2022;1:72–79

DOI: https://doi.org/10.37349/edd.2022.00006

Full Text PDF

3036 67 3

Open Access Review

Zebrafish as a model for drug induced liver injury: state of the art and beyond

Zebrafish as a preclinical drug induced liver injury (DILI) model provides multiple advantages ranging from ease of breeding and maintenance, availability of different strains and transgenic fish am

Published: April 26, 2023 Explor Dig Dis. 2023;2:44–55

DOI: https://doi.org/10.37349/edd.2023.00017

Full Text PDF

4647 134 3

PMC Articles

See all